160 related articles for article (PubMed ID: 10093625)
21. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
[TBL] [Abstract][Full Text] [Related]
22. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ
J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
[No Abstract] [Full Text] [Related]
23. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
Khasraw M; Bell R; Dang C
Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
Brambilla C; Rossi A; Bonfante V; Ferrari L; Villani F; Crippa F; Bonadonna G
Cancer Treat Rep; 1986 Feb; 70(2):261-6. PubMed ID: 3456271
[TBL] [Abstract][Full Text] [Related]
25. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.
Ibrahim NK; Frye DK; Buzdar AU; Walters RS; Hortobagyi GN
Arch Intern Med; 1996 Apr; 156(8):882-8. PubMed ID: 8774207
[TBL] [Abstract][Full Text] [Related]
26. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
Ormrod D; Holm K; Goa K; Spencer C
Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen HT; Klijn JG; van Oosterom AT
Br J Cancer; 1998 Jun; 77(12):2257-63. PubMed ID: 9649142
[TBL] [Abstract][Full Text] [Related]
28. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
29. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
Kaklamani VG; Gradishar WJ
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
[TBL] [Abstract][Full Text] [Related]
30. Overview of epirubicin-based adjuvant therapy in breast cancer.
Untch M; von Koch F; Kahlert S; Konecny G
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S41-5. PubMed ID: 15959941
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
Ibrahim NK; Hortobagyi GN; Ewer M; Ali MK; Asmar L; Theriault RL; Fraschini G; Frye DK; Buzdar AU
Cancer Chemother Pharmacol; 1999; 43(6):471-8. PubMed ID: 10321507
[TBL] [Abstract][Full Text] [Related]
32. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
[TBL] [Abstract][Full Text] [Related]
33. [Epirubicin--results in breast cancer].
Hartlapp JH
Onkologie; 1986 Aug; 9 Suppl 1():3-7. PubMed ID: 3528968
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.
Yang RX; Ren HX; Zhuang L; Gao CL; Dong C; Luo CX; Wang XN; Feng EF; He JC
Arzneimittelforschung; 2012 Dec; 62(12):677-81. PubMed ID: 23203544
[TBL] [Abstract][Full Text] [Related]
35. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.
Coukell AJ; Faulds D
Drugs; 1997 Mar; 53(3):453-82. PubMed ID: 9074845
[TBL] [Abstract][Full Text] [Related]
36. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
Fossati R; Confalonieri C; Torri V; Ghislandi E; Penna A; Pistotti V; Tinazzi A; Liberati A
J Clin Oncol; 1998 Oct; 16(10):3439-60. PubMed ID: 9779724
[TBL] [Abstract][Full Text] [Related]
38. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Plosker GL; Faulds D
Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
[TBL] [Abstract][Full Text] [Related]
39. New anthracycline analogs in advanced breast cancer.
Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
[TBL] [Abstract][Full Text] [Related]
40. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
Mao Z; Shen K; Zhu L; Xu M; Yu F; Xue D; Li H; Xue C
Oncol Res Treat; 2019; 42(7-8):405-413. PubMed ID: 31104059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
